论文部分内容阅读
目的探讨血管内皮生长因子(VEGF)、抗酒石酸酸性磷酸酶5b(TRACP-5b)在多发性骨髓瘤(MM)患者血清中的表达及其与临床分期及骨质破坏的关系。方法应用酶联免疫吸附法(ELISA)定量检测MM患者(MM组)和非MM患者(对照组)血清VEGF与TRACP-5b的水平。结果MM组血清VEGF、TRACP-5b含量均明显高于对照组(P<0.01);MM组血清VEGF水平随临床分期增高呈递增趋势(P<0.01);骨损程度评分组间TRACP-5b水平差异存在显著性(P<0.05);12例经酞咪呱啶酮(沙利度胺)及双磷酸盐治疗后,血清VEGF及TRACP-5b含量明显下降(P<0.01)。结论MM患者血清VEGF、TRACP-5b含量明显高。VEGF与MM病程有关,TRACP-5b水平可反应MM骨损程度;两者似可作为MM治疗后随访病情的监测指标。
Objective To investigate the expression of vascular endothelial growth factor (VEGF) and tartrate-resistant acid phosphatase 5b (TRACP-5b) in the serum of patients with multiple myeloma (MM) and its relationship with clinical stage and bone destruction. Methods Serum levels of VEGF and TRACP-5b in patients with MM (MM group) and non-MM patients (control group) were quantitatively determined by enzyme-linked immunosorbent assay (ELISA) Results The levels of VEGF and TRACP-5b in MM group were significantly higher than those in control group (P <0.01). The levels of serum VEGF in MM group increased with the clinical stage (P <0.01), and the level of TRACP-5b The difference was significant (P <0.05). The levels of VEGF and TRACP-5b in 12 cases were significantly decreased (P <0.01) after treatment with thalidomide and diphosphate. Conclusion The serum levels of VEGF and TRACP-5b in patients with MM are significantly higher. VEGF and MM duration, TRACP-5b level can reflect the degree of MM bone damage; both may be used as MM follow-up monitoring of disease indicators.